Markets

Reported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients

Oct 19, 2026 · 02:51 AM ET· updated 1h ago

New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation

Why It Matters

AbbVie tested a new cancer medicine called ABBV-706. Early results show it helped some patients live longer and tumors shrank in many cases.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ABBV286.88

+3.48 (+1.23%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.